keyword
MENU ▼
Read by QxMD icon Read
search

bevacizumab with folfox in metastatic colon cancer

keyword
https://www.readbyqxmd.com/read/27309405/when-a-good-call-leads-to-a-bad-connection-colovesical-fistula-in-colorectal-cancer-treated-with-bevacizumab
#1
Jeffrey Chen, Roger D Smalligan, Suhasini Nadesan
INTRODUCTION: Colorectal cancer is the third most common cancer in the United States. The use of bevacizumab (Avastin), a vascular endothelial growth factor (VEGF) inhibitor, has been increasing due to observed improvement in metastatic colon cancer survival, but so has the incidence of bowel perforation. We present one unusual complication of bowel perforation, a colovesical fistula in a colorectal cancer patient treated with bevacizumab. CASE PRESENTATION: A 54-year-old white male diagnosed with Stage IV colorectal cancer was treated with folinic acid, leucovorin, fluorouracil, oxaliplatin (FOLFOX) and bevacizumab...
August 2016: Hospital Practice (Minneapolis)
https://www.readbyqxmd.com/read/27003552/factors-associated-with-adherence-rates-for-oral-and-intravenous-anticancer-therapy-in-commercially-insured-patients-with-metastatic-colon-cancer
#2
Brian S Seal, Sibyl Anderson, Kenneth M Shermock
BACKGROUND: Over the past decade, oncology therapies have trended toward orally administered regimens, and there has been growing attention on evaluation of factors that affect adherence. There has not been a rigorous investigation of factors associated with adherence to intravenous (i.v.) and oral anticancer drugs in the setting of metastatic colorectal cancer (mCRC). OBJECTIVES: To (a) assess potential patient-specific factors related to adherence to mCRC chemotherapy regimens and (b) compare adherence with IV versus oral dosage forms...
March 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/26327923/precision-medicine-in-colorectal-cancer-the-molecular-profile-alters-treatment-strategies
#3
REVIEW
Nguyen H Tran, Ludmila L Cavalcante, Sam J Lubner, Daniel L Mulkerin, Noelle K LoConte, Linda Clipson, Kristina A Matkowskyj, Dustin A Deming
When considering treatment options for patients with metastatic colorectal cancer (mCRC), molecular profiling has become a pivotal component in guiding clinical decisions. FOLFOX and FOLFIRI (fluorouracuil, leucovorin plus oxaliplatin or ininotecan, respectively) are the standard base regimens used for the treatment of mCRC. Biologic agents, such as the epidermal growth factor receptor (EGFR) targeted therapies, cetuximab and panitumumab and the vascular endothelial growth factor monoclonal antibody, bevacizumab, are safe and effective in the first-line setting...
September 2015: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/26244985/impact-of-pre-treatment-lactate-dehydrogenase-levels-on-prognosis-and-bevacizumab-efficacy-in-patients-with-metastatic-colorectal-cancer
#4
RANDOMIZED CONTROLLED TRIAL
Alessandro Passardi, Emanuela Scarpi, Stefano Tamberi, Luigi Cavanna, Davide Tassinari, Annalisa Fontana, Sara Pini, Ilaria Bernardini, Caterina Accettura, Paola Ulivi, Giovanni Luca Frassineti, Dino Amadori
BACKGROUND: To investigate the impact of pre-treatment lactate dehydrogenase (LDH) levels on the outcome of patients with metastatic colorectal cancer treated with first-line chemotherapy with or without the anti-VEGF monoclonal antibody, bevacizumab, in a phase III prospective multicentre randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial. METHODS: Three hundred and seventy patients enrolled onto the ITACa first-line trial were considered for this study, 176 receiving chemotherapy (either FOLFIRI or FOLFOX) plus bevacizumab and 194 receiving chemotherapy only...
2015: PloS One
https://www.readbyqxmd.com/read/26199249/-clinical-response-of-metastatic-colon-cancer-to-chemotherapy-with-s-1-and-oxaliplatin-a-case-report
#5
Tomonori Morimoto, Yoshihiro Yata, Yoshikuni Yonenaga, Kouji Hanaki, Masahiro Mise, Shunichi Higaside, Yuuji Kanda, Hideki Noda
Chemotherapy with S-1 and oxaliplatin is a new treatment for metastatic colorectal cancer. We present the first case of S-1, oxaliplatin, and bevacizumab therapy in our hospital. The patient was a 69-year-old woman with ascending colon cancer and multiple lung and liver metastases. She tended to suffer from constipation; stenoses at the cecum and colon cancer were detected by colon fiberscopy. Following surgical resection of the primary tumor, the patient received systemic chemotherapy with S-1, oxaliplatin, and bevacizumab...
June 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/26176048/addition-of-bevacizumab-to-first-line-chemotherapy-for-metastatic-colorectal-cancer
#6
Soichi Tsutsumi, Takaaki Fujii, Satoru Yamaguchi, Toshinaga Suto, Reina Yajima, Hiroki Morita, Toshihide Kato, Takayuki Asao, Hiroyuki Kuwano
BACKGROUND/AIMS: We evaluated the efficacy and safety of bevacizumab for metastatic colorectal cancer patients. METHODOLOGY: All unresectable metastatic colorectal cancer patients who began receiving bevacizumab at participating facilities from 2006 to 2011 were retrospectively analyze to determine the safety and efficacy. The primary end points were Progression Free Survival (PFS) and Overall Survival (OS). The secondary end points were adverse events. RESULTS: A total of 101 patients were enrolled in the study...
May 2014: Hepato-gastroenterology
https://www.readbyqxmd.com/read/26074686/different-treatment-strategies-and-molecular-features-between-right-sided-and-left-sided-colon-cancers
#7
REVIEW
Hong Shen, Jiao Yang, Qing Huang, Meng-Jie Jiang, Yi-Nuo Tan, Jian-Fei Fu, Li-Zhen Zhu, Xue-Feng Fang, Ying Yuan
The colon is derived from the embryological midgut and hindgut separately, with the right colon and left colon having different features with regards to both anatomical and physiological characteristics. Cancers located in the right and left colon are referred to as right colon cancer (RCC) and left colon cancer (LCC), respectively, based on their apparent anatomical positions. Increasing evidence supports the notion that not only are there differences in treatment strategies when dealing with RCC and LCC, but molecular features also vary between them, not to mention the distinguishing clinical manifestations...
June 7, 2015: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/25994542/-sequential-inhibition-of-angiogenesis-in-metastatic-colorectal-cancer-activity-and-efficacy-of-aflibercept
#8
Concetta Martines, Stefano Cordio, Roberto Bordonaro
We report a case of a young adult affected by an adenocarcinoma of the ascending colon with synchronous, unresectable liver metastases, diagnosed on April, 2011. The patient received a first-line of bio-chemotherapy with standard folfox regimen in association with bevacizumab. Deriving from which a good partial remission of the disease with its conversion to operability; so he underwent a right hemicolectomy with liver metastasectomy. Eleven months after radical surgery, the patient experimented an intrahepatic progression of the tumour, so he started a second-line therapy with FOLFIRI regimen plus aflibercept...
May 2015: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/25926352/phase-ii-trial-of-preoperative-radiation-with-concurrent-capecitabine-oxaliplatin-and-bevacizumab-followed-by-surgery-and-postoperative-5-fluorouracil-leucovorin-oxaliplatin-folfox-and-bevacizumab-in-patients-with-locally-advanced-rectal-cancer-5-year-clinical
#9
Jerome C Landry, Yang Feng, Roshan S Prabhu, Steven J Cohen, Charles A Staley, Richard Whittington, Elin Ruth Sigurdson, Halla Nimeiri, Udit Verma, Al Bowen Benson
LESSONS LEARNED: The 5-year oncologic outcomes from the trial regimen were excellent. However, the neoadjuvant and surgical toxicity of this regimen was significant and was the primary reason for the low compliance with adjuvant systemic therapy.Due to the lack of an improvement in the pathologic complete response rate, the substantial associated toxicity, and the negative phase III trials of adjuvant bevacizumab in colon cancer, this regimen will not be pursued for further study. BACKGROUND: The addition of bevacizumab to chemotherapy improves overall survival for metastatic colorectal cancer...
June 2015: Oncologist
https://www.readbyqxmd.com/read/25731325/-a-case-of-metastatic-colorectal-cancer-that-reduced-in-size-after-re-challenging-with-an-anti-egfr-monoclonal-antibody
#10
Mutsumi Fukunaga, Ken Nakata, Akihito Babaya, Katsushu Shimizu, Takahiko Ishigaki, Takeshi Ebihara, Satoshi Okubo, Fumitaka Kato, Kouji Amano, Hiromitsu Hoshino, Ryohei Kawabata, Jun Yamamura, Shunji Kamigaki, Akihiro Usui, Naoki Ikeda, Tameyoshi Yamamoto, Tomono Kawase, Yutaka Kimura, Hiroki Ohzato
A 58-year-old woman was confirmed as having multiple liver metastases after undergoing a high anterior resection for a sigmoid colon tumor. She was administered bevacizumab+FOLFOX as the first regimen and bevacizumab+FOLFIRI and S-1 and irinotecan (IRIS)therapy as the second regimen. During this treatment she also underwent hepatectomy 3 times and radiofrequency ablation once. She was administered panitumumab+irinotecan as the third regimen and, due to the presence of multiple pulmonary metastases, was subsequently considered to have had a partial response (PR)...
November 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25731321/-a-case-of-liver-metastasis-from-sigmoid-colon-cancer-treated-effectively-by-second-line-chemotherapy
#11
Kentaro Gokita, Katsunori Ami, Yutaro Matsunaga, Keiichi Fujiya, Nana Ohshima, Hidetoshi Amagasa, Hideaki Ganno, Kenichiro Imai, Akira Fukuda, Takeshi Nagahama, Masayuki Ando, Hidetaka Akita, Shikofumi Tei, Youichi Okada, Kuniyoshi Arai
A case of successful chemotherapy for a metachronous liver metastasis following resection for sigmoid colon cancer is presented. A 51-year-old man underwent sigmoidectomy, ileocecal resection, and descending colon colostomy for sigmoid colon cancer with ileum invasion. Six courses of FOLFOX4 were performed as adjuvant chemotherapy. One year after sigmoidectomy, a liver metastasis was detected on computed tomography (CT) examination. Chemotherapy with FOLFOX+bevacizumab was restarted. Three courses were administered, but hepatic dysfunction occurred after the second and third courses, and FOLFOX was discontinued...
November 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25605315/insulin-like-growth-factor-ii-producing-metastatic-colon-cancer-with-recurrent-hypoglycemia
#12
Satoshi Teramae, Hiroshi Miyamoto, Naoki Muguruma, Yasuyuki Okada, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Masako Kimura, Yoshimi Bando, Tetsuji Takayama
A 45-year-old man was referred to our hospital and found to have a tubular adenocarcinoma of the descending colon with multiple liver metastases. During hospitalization, the patient suffered recurrent hypoglycemic attacks that required intravenous 50% glucose infusion. He was diagnosed with non-islet cell tumor hypoglycemia (NICTH) because the colon cancer tissue obtained by biopsy was strongly stained for insulin-like growth factor-II (IGF-II) by immunohistochemistry. He received chemotherapy with oxaliplatin, 5-FU and leucovorin (FOLFOX) plus bevacizumab (Bmab), and showed a partial response...
February 2015: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/25542326/management-of-malignancy-related-ascites
#13
Anne Marie C Flaherty
A 65-year-old Polish immigrant named T. J. was diagnosed with metastatic colon cancer in January 2012 when he presented with obstructing sigmoid colon cancer and liver metastases. A diverting colostomy as well as biopsy of his liver metastases was performed and chemotherapy with FOLFOX (5-fluorouracil [5-FU], leucovorin, oxaliplatin) and bevacizumab was initiated. After three months, he transitioned to maintenance therapy with infusional 5-FU and bevacizumab until he progressed in August 2012. Oxaliplatin was reintroduced and he responded until he developed progressive neuropathy in November and his therapy was changed to FOLFIRI (5-FU, leucovorin, irinotecan) and bevacizumab...
January 2015: Oncology Nursing Forum
https://www.readbyqxmd.com/read/25289100/colon-cancer-metastasis-to-mediastinal-lymph-nodes-without-liver-or-lung-involvement-a-case-report
#14
Mustapha M El-Halabi, Said A Chaaban, Joseph Meouchy, Seth Page, William J Salyers
Colon cancer is the second most common type of cancer in females and the third in males, worldwide. The most common sites of colon cancer metastasis are the regional lymph nodes, liver, lung, bone and brain. In this study, an extremely rare case of colon adenocarcinoma with extensive metastasis to the mediastinal lymph nodes without any other organ involvement is presented. A 44-year-old Caucasian male presented with abdominal pain, a change in bowel habits, melena and weight loss. Colonoscopy revealed a large friable, ulcerated, circumferential mass in the ascending colon...
November 2014: Oncology Letters
https://www.readbyqxmd.com/read/25209093/adaptation-of-international-guidelines-for-metastatic-colorectal-cancer-an-asian-consensus
#15
Ann-Lii Cheng, Jin Li, Ashok K Vaid, Brigette Buig Yue Ma, Catherine Teh, Joong B Ahn, Maximino Bello, Chaiyut Charoentum, Li-Tzong Chen, Gilberto de Lima Lopes, Gwo F Ho, Hwai L Kong, Ka O Lam, Tian S Liu, Young S Park, Virote Sriuranpong, Aru W Sudoyo, Jaw-Yuan Wang, Jun Zhang, Su Z Zhang, Fortunato Ciardiello, Clause-Henning Köhne, Michael Shaw, Tae Won Kim
Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice...
September 2014: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/25068003/patients-with-multiple-synchronous-colonic-cancer-hepatic-metastases-benefit-from-enrolment-in-a-liver-first-approach-protocol
#16
Dimitrios Kardassis, Achilleas Ntinas, Dimosthenis Miliaras, Alexandros Kofokotsios, Konstantinos Papazisis, Dionisios Vrochides
AIM: To assess a protocol for treating patients with multiple synchronous colonic cancer liver metastases, which are unresectable in one stage. METHODS: Patients enrolled in the "liver first" protocol presented with colon-only (not rectal) cancer and multiple synchronous hepatic metastases (type II or III). All patients showed good performance status (ECOG PS 0-1) and were treated with curative intent. Complete oncologic staging including positron emission tomography-computed tomography was performed in order to rule out extrahepatic disease...
July 27, 2014: World Journal of Hepatology
https://www.readbyqxmd.com/read/24472471/how-we-treat-metastatic-colon-cancer-in-older-adults
#17
Hanna K Sanoff, Richard M Goldberg
The past decade has seen unprecedented advancements in our ability to treat patients with metastatic colorectal cancer. When applying these advances--hepatic resection and multi-agent chemotherapy--to the care of older patients, it is essential to first perform some assessment of function beyond performance status and to elicit feedback from the patient about how he/she values quality versus quantity of life. For robust older patients with potentially surgically resectable oligometastatic cancer, we recommend a standard approach of surgery with perioperative chemotherapy...
October 2013: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/24419719/pulmonary-edema-caused-by-levofolinate-treatment-in-patients-with-liver-metastases-from-colorectal-cancer
#18
Nobuhiko Taniai, Hiroshi Yoshida, Masato Yoshioka, Youichi Kawano, Junji Ueda, Eiji Uchida
A liver tumor metastatic from a sigmoid colon carcinoma was diagnosed in a 70-year-old man. Because hepatectomy was not indicated, the patient was treated with a combination of oxaliplatin, levofolinate, and fluorouracil (5-FU) (modified FOLFOX 6 regimen). After 15 cycles of chemotherapy, this regimen was considered to have been ineffective; therefore, treatment was started with the topoisomerase inhibitor irinotecan and an intravenous infusion of 5-FU and levofolinate (FOLFIRI). After receiving irinotecan and levofolinate, the patient had chills, a severe cough, and dyspnea...
2013: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/23957924/partial-response-after-transcatheter-arterial-infusion-chemotherapy-in-a-patient-with-systemic-chemotherapy-resistant-unresectable-colon-cancer-and-hepatic-metastasis-case-report
#19
Katsuji Sawai, Takanori Goi, Kenji Koneri, Kanji Katayama, Akio Yamaguchi
We report here a case of partial response to hepatic arterial infusion chemotherapy in a patient who developed serious hepatic failure due to unresectable colorectal cancer and hepatic metastasis and showed resistance to systemic chemotherapy with molecular targeted drugs, mFOLFOX6, and FOLFIRI. The patient was a 60-year-old woman who underwent sigmoidectomy for sigmoid colon cancer, lateral posterior hepatic segmentectomy for metastatic liver cancer, and postoperative radiation therapy for metastatic lung cancer...
August 17, 2013: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/23792568/off-label-use-of-cetuximab-plus-sorafenib-and-panitumumab-plus-regorafenib-to-personalize-therapy-for-a-patient-with-v600e-braf-mutant-metastatic-colon-cancer
#20
Mhd Yaser Al-Marrawi, Bikramajit Singh Saroya, Matthew C Brennan, Zhaohai Yang, Thomas M Dykes, Wafik S El-Deiry
Sorafenib, the first agent developed to target BRAF mutant melanoma, is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer, and is currently in clinical trials for thyroid, lung and brain cancer. Colorectal cancer with V600E BRAF mutation has shown relative resistance to standard chemotherapy regimens, as well as lack of efficacy to vemurafenib in clinical trials. New treatments are needed for BRAF-mutant colorectal cancer. We report a case of a patient with BRAF-mutant metastatic colon cancer whose disease had progressed on FOLFOX plus bevacizumab and subsequent FOLFIRI plus cetuximab...
August 2013: Cancer Biology & Therapy
keyword
keyword
114967
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"